The medication of teratoma patients must be scientific and reasonable

Teratoma is a common disease in women. It is a benign ovarian tumor that can occur at any age, but is more common in middle-aged women. According to experts, the effect of drug treatment alone is not good for teratoma. Once discovered, it must be surgically removed. Drugs are used for postoperative adjuvant therapy. Teratoma patients must use drugs scientifically and rationally.

Once a teratoma is diagnosed, early surgical resection is necessary to prevent benign teratoma from becoming malignant due to delayed surgery, and to prevent infection, rupture, bleeding and complications. The key point of teratoma surgery is to completely remove the tumor. For ovarian and testicular tumors, one ovary or testicle should be removed. For sacrococcygeal teratoma, the coccyx must be removed at the same time to avoid residual pluripotent cells that may cause tumor recurrence.

The treatment principle of malignant teratoma is combined adjuvant therapy, with conventional chemotherapy for 1.5 to 2 years after surgical resection, usually cisplatin, vinblastine or vincristine, and bleomycin. In recent years, combined chemotherapy with cisplatin, doxorubicin, ifosfamide and other chemotherapy drugs is recommended.

Radiotherapy is only used for cases of malignant teratoma with clear microscopic or macroscopic residuals. The radiotherapy dose is preferably 25Gy for microscopic residuals and 35Gy for macroscopic residuals. For those who have undergone complete surgical resection, chemotherapy is advocated in recent years, and radiotherapy is used with caution to avoid delayed damage to reproductive organs and bone development during radiotherapy. It is divided into: benign ovarian tumors include serous cystadenoma, mucinous cystadenoma and benign cystic teratoma. It has two major characteristics: one is that it is more common in bilaterality; the other is that it is easy to recur, with a recurrence rate of 2%.